A randomised, open-label, 5-period, cross-over trial to assess the pharmacokinetics and safety of 3 oral solid formulations of buloxibutid (C21) in healthy male and female participants

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520702-35-00

Acronym

VP-C21-014

Enrollment

Registered

2025-04-22

Start date

2025-05-14

Completion date

2025-08-25

Last updated

2025-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopahtic pulmonary fibrosis

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026